Neurofibromatosis type 1–related hydrocephalus: causes and treatment considerations

被引:0
|
作者
Jonathan Roth
Shlomi Constantini
Giuseppe Cinalli
机构
[1] Tel-Aviv University,Department of Pediatric Neurosurgery, Dana Children’s Hospital, Tel
[2] The Gilbert Israeli International Neurofibromatosis Center GIINFC,Aviv Medical Center
[3] Santobono-Pausilipon Children’s Hospital,Pediatric Neurosurgery
来源
Child's Nervous System | 2020年 / 36卷
关键词
Neurofibromatosis 1; Hydrocephalus; Optic pathway glioma; Endoscopic third ventriculostomy; Shunt;
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence of hydrocephalus among patients with neurofibromatosis type I (NF1) is estimated to be between 1 and 13%. Most hydrocephalic causes are obstructive—aqueductal webs, chiasmatic-hypothalamic tumors, and thalamic mass effect related to NF changes. Other NF1-related conditions may mimic the clinical presentation of hydrocephalus and should be ruled out while evaluating children with headaches. These include brain tumors and moyamoya syndrome. Treatment of NF1-related hydrocephalus should be personally tailored, including tumor resection or debulking, shunts, and endoscopic procedures such as septostomy and third ventriculostomy. Despite these personalized treatments, many of the primary treatments (including shunts and endoscopic procedures) fail, and patients should be screened and followed accordingly. In the current manuscript, we review the causes of NF1-related hydrocephalus, as well as treatment options.
引用
收藏
页码:2385 / 2390
页数:5
相关论文
共 50 条
  • [1] Neurofibromatosis type 1-related hydrocephalus: causes and treatment considerations
    Roth, Jonathan
    Constantini, Shlomi
    Cinalli, Giuseppe
    [J]. CHILDS NERVOUS SYSTEM, 2020, 36 (10) : 2385 - 2390
  • [2] Neurofibromatosis Type 1-Related Hydrocephalus: Treatment Options and Considerations
    Roth, Jonathan
    Ber, Roee
    Constantini, Shlomi
    [J]. WORLD NEUROSURGERY, 2019, 128 : E664 - E668
  • [3] Neurofibromatosis Type 1 Related Hydrocephalus
    Roth, Jonathan
    Constantini, Shlomi
    [J]. NEUROLOGY INDIA, 2021, 69 : S368 - S371
  • [4] Treatment of Neurofibromatosis Type 1
    Sabatini, Caterina
    Milani, Donatella
    Menni, Francesca
    Tadini, Gianluca
    Esposito, Susanna
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (06) : 1 - 11
  • [5] Treatment of Neurofibromatosis Type 1
    Caterina Sabatini
    Donatella Milani
    Francesca Menni
    Gianluca Tadini
    Susanna Esposito
    [J]. Current Treatment Options in Neurology, 2015, 17
  • [6] Treatment of ADHD in neurofibromatosis type 1
    Mautner, VF
    Kluwe, L
    Thakker, SD
    Leark, RA
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2002, 44 (03): : 164 - 170
  • [7] DIETARY TREATMENT FOR NEUROFIBROMATOSIS TYPE 1
    Stevenson, D. A.
    Summers, M. A.
    Johnson, B.
    Murray, C.
    Hanson, H.
    Stevens, A.
    Viskochil, D. H.
    Carey, J. C.
    Vasiljevski, E.
    Schindeler, A.
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2019, 179 (04) : 701 - 701
  • [8] Challenges in treatment of neurofibromatosis type 1
    Babovic-Vuksanovic, Dusica
    Deyle, David R.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 : S116 - S116
  • [9] Recommendations for the treatment of neurofibromatosis type 1
    Pinson, S
    Créange, A
    Barbarot, S
    Stalder, JF
    Chaix, Y
    Rodriguez, D
    Sanson, M
    Bernheim, A
    d'Incan, M
    Doz, F
    Stoll, C
    Combemale, P
    Kalifa, C
    Zeller, J
    Teillac-Hamel, D
    Lyonnet, S
    Zerah, M
    Lacour, JP
    Guillot, B
    Wolkenstein, P
    [J]. JOURNAL FRANCAIS D OPHTALMOLOGIE, 2002, 25 (04): : 423 - 433
  • [10] Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape
    Armstrong, Amy E.
    Brossier, Nicole M.
    Hirbe, Angela C.
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2020, 4 (07): : 488 - 490